Cover Image
市場調查報告書

青少年黃斑部病變(Stargardt氏病)的全球市場

Global Juvenile Degeneration (Stargardt Disease) Market Research Report - Forecast to 2027

出版商 Market Research Future 商品編碼 617086
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
青少年黃斑部病變(Stargardt氏病)的全球市場 Global Juvenile Degeneration (Stargardt Disease) Market Research Report - Forecast to 2027
出版日期: 2017年12月24日 內容資訊: 英文 119 Pages
簡介

本報告提供全球青少年黃斑部病變(Stargardt氏病)的市場調查,市場定義和概要,市場成長的各種影響因素及市場機會分析,宏觀經濟指標,技術趨勢,價值鏈,投資可行性分析,各診斷技術、設備、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,主要企業簡介等彙整。

第1章 序文

第2章 簡介

  • 定義
  • 調查範圍

第3章 調查手法

第4章 市場動態

  • 成長推動因素
  • 阻礙成長要素
  • 市場機會
  • 課題
  • 宏觀經濟指標
  • 技術趨勢、評估

第5章 市場影響因素分析

  • 波特的五力分析
  • 價值鏈分析
  • 投資可行性分析
  • 價格分析

第6章 全球青少年黃斑部病變(Stargardt氏病) 市場分析、預測:各診斷法

  • 簡介
  • 市場估計、預測
    • 螢光素螢光眼底造影 (FA)
    • 眼底自發螢光 (FAF)
    • 光學同調斷層掃描 (OCT)
    • 視網膜電圖 (ERG)

第7章 全球青少年黃斑部病變(Stargardt氏病) 市場分析、預測:各設備

  • 簡介
  • 市場估計、預測
    • 擴大眼鏡
    • 放大鏡
    • 讀出用望遠鏡

第8章 全球青少年黃斑部病變(Stargardt氏病) 市場分析、預測:各終端用戶

  • 簡介
  • 市場估計、預測
    • 醫院、眼科診療所
    • 研究機關、學術機構

第9章 地區分析

  • 簡介
  • 南北美洲
    • 北美
      • 美國
      • 加拿大
    • 南美
  • 歐洲
    • 西歐
      • 德國
      • 法國
      • 義大利
      • 西班牙
      • 英國
      • 其他
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 中東、非洲
    • UAE
    • 沙烏地阿拉伯
    • 阿曼
    • 科威特
    • 卡達
    • 其他

第10章 企業環境

  • 簡介
  • 市場佔有率分析
  • 主要的發展、策略

第11章 企業簡介

  • Alkeus Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Allergan PLC
  • Pfizer
  • PfBausch + Lomb
  • Gilead Sciences Inc.
  • Gilead Sciences Inc.
  • 其他

第12章 總論

第13章 附錄

目錄

Introduction

Juvenile Macular Degeneration is the genetic eye disorder that affects the vision further leading to vision loss. Generally, this disorder affects the specialized light-sensitive tissue present in the retina. Precisely, this type of macular degeneration affects the center of the retina which is knewn as macula. The function of macula is to add sharpness to the central vision. This region is responsible for handling detailed tasks such as recognizing faces, driving, and reading. Most of the people suffering from stargardt macular degeneration, produce a bodily fluid known as lipofuscin, that is responsible for the cellular regeneration underlying the macula. Moreover the over time accumulation of this fluid causes cellular damage. Furthermore, the affected individuals also show the symptoms of color blindness. Usually, the signs and symptoms appear in late childhood which is responsible for disease progression.

Notably, increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies are promoting the growth of juvenile macular degeneration market globally. It is observed that the research and development cost for the Stargardt disease is very high leading to the massive prices of the end products.

Despite these drivers, there are some issues associated with juvenile macular degeneration market. Lack of awareness among people may hinder the growth of the market to an extent.

Geographically, Europe region is commanding the largest market share owing to the increasing prevalence of Stargardt disease.

The global juvenile macular degeneration (Stargardt disease) market is expected to reach USD 1593.885 million in 2027 from USD 780.995 million in 2016. This market is expected to grow at a stable CAGR of 6.7% during the forecast period 2017-2027.

Key Players

The key players for the Astellas Pharma Inc., Sanofi S.A., Acucela Inc., Alkeus Pharma, Copernicus Therapeutics, Inc., Ophthotech Corporation, Bayer AG, Oxford BioMedica plc, Grupo Ferrer Internacional, and others

Study objectives

To provide a detailed analysis of the market structure along with a forecast of the various segments and sub-segments of global juvenile macular degeneration (Stargardt disease) market.

  • To provide a comprehensive analysis of juvenile macular degeneration industry and its sub-segments in the global market, thereby providing a detailed structure of the industry.
  • To provide detailed insights into the factors driving and restraining the growth of global juvenile macular degeneration (Stargardt disease) market.
  • To estimate the market size of global juvenile macular degeneration (Stargardt disease) from 2014 to 2027. Wherein, 2014 & 2015 would be the historical period, 2016 shall be the base year, and 2017 - 2027 will be forecast period for the study.
  • To analyze global juvenile macular degeneration (Stargardt disease) market, on the basis of four main geographies namely, Europe, Americas, Asia-Pacific, and The Middle East & Africa.
  • To compare the products with respect to the various players in the market
  • To provide country-wise market value analysis for various segments of juvenile macular degeneration (Stargardt disease) market
  • To understand the demand-supply scenario and provide a gap analysis of the industry
  • To analyze and provide upcoming technologies and trends in juvenile macular degeneration (Stargardt disease) market
  • To provide strategic profiling of key companies (manufacturers and distributors) present across the globe, and comprehensively analyze their competitiveness/competitive landscape in this market.

Target Audience

  • Pharmaceutical and Biotech Industries
  • Potential Investors
  • Medical Research Institutes
  • Key Executive (CEO and COO) and Strategy Growth Manager
  • Research Companies

Key Findings

  • the major players operating in this market are Acucela Inc., Ophthotech Corporation, Sanofi S.A., Lin BioScience, Inc., Alkeus Pharma, Carl Zeiss AG, and others.
  • Fluorescein Angiography (FA) dominates the juvenile macular degeneration (Stargardt disease) market with a share of 34.6%, as compared to other diagnosis types.
  • On the basis of management, the market for magnifying spectacles is projected to reach USD 597.642 million by the end of 2027 at a CAGR of 7.0%, during 2017 to 2027.
  • On the basis of the end-user, hospitals, and eye clinics accounted for the largest market share with 62.2% of the global juvenile macular degeneration market
  • On the basis of region, Asia-Pacific region is projected to be the fastest growing region at a CAGR of 7.3%, during the forecast period.

The report also covers regional analysis

Americas

    • The U.S.
    • Canada
  • South America

Europe

    • Germany
    • France
    • Italy
    • U.K
    • Spain
    • Rest of Western Europe
  • Eastern Europe

Asia-Pacific

    • China
    • Japan
    • India
    • Australia
    • Republic of Korea
    • Rest of Asia Pacific

The Middle East & Africa

  • The Middle East
  • Africa

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
    • 2.2.1 Research Objective
    • 2.2.2 Assumptions
    • 2.2.3 Limitations

Chapter 3. Research Methodology

  • 3.1 Introduction
  • 3.2 Primary Research
  • 3.3 Secondary research
  • 3.4 Market Size Estimation

Chapter 4. Market Dynamics

  • 4.1 Drivers
  • 4.2 Restrains
  • 4.3 Opportunities
  • 4.4 Challenges
  • 4.5 Macroeconomic Indicators
  • 4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

  • 5.1 Porters Five Forces Analysis
    • 5.1.1 Bargaining Power of Suppliers
    • 5.1.2 Bargaining Power of Buyers
    • 5.1.3 Threat of New Entrants
    • 5.1.4 Threat of Substitutes
    • 5.1.5 Intensity of Rivalry
  • 5.2 Value Chain Analysis
  • 5.3 Investment Feasibility Analysis
  • 5.4 Pricing Analysis

Chapter 6. Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis

6.1

  • 6.2 Fluroscein Angiography (FA)
    • 6.2.1 Market Estimates & Forecast, 2017 - 2023
  • 6.3 Fundus Autofluorescence (FAF)
    • 6.3.1 Market Estimates & Forecast, 2017 - 2023
  • 6.4 Optical Coherence Tomography (OCT)
    • 6.4.1 Market Estimates & Forecast, 2017 - 2023
  • 6.5 Electroretinography
    • 6.5.1 Market Estimates & Forecast, 2017 - 2023

Chapter 7. Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Devices

7.1

  • 7.2 Magnifying Spectacles
    • 7.2.1 Market Estimates & Forecast, 2017 - 2023
  • 7.3 Magnifiers
    • 7.3.1 Market Estimates & Forecast, 2017 - 2023
  • 7.4 Reading telescopes
    • 7.4.1 Market Estimates & Forecast, 2017 - 2023

Chapter 8 Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End Users

  • 8.1 Introduction
  • 8.2 Hospitals & Eye Clinics
    • 8.2.1 Market Estimates & Forecast, 2017 - 2023
  • 8.3 Research & Academic Institutes
    • 8.3.1 Market Estimates & Forecast, 2017 - 2023

Chapter 9. Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region

  • 9.1 Introduction
  • 9.2 America
    • 9.2.1 North America
      • 9.2.1.1 US
      • 9.2.1.1 Canada
    • 9.2.2 South America
  • 9.3 Europe
    • 9.3.1 Western Europe
      • 9.3.1.1 Germany
      • 9.3.1.2 France
      • 9.3.1.3 Italy
      • 9.3.1.4 Spain
      • 9.3.1.5 UK
      • 9.3.1.6 Rest of Western Europe
    • 9.3.2 Eastern Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Republic of Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 The Middle East & Africa
    • 9.5.1 United Arab Emirates
    • 9.5.2 Saudi Arabia
    • 9.5.3 Oman
    • 9.5.4 Kuwait
    • 9.5.5 Qatar
    • 9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

  • 10.1 Introduction
  • 10.2 Market Share Analysis
  • 10.3 Key Development & Strategies
    • 10.3.1 Key Developments

Chapter 11 Company Profiles

  • 11.1 Alkeus Pharmaceuticals Inc.
    • 11.1.1 Company Overview
    • 11.1.2 Product Overview
    • 11.1.3 Financials
    • 11.1.4 SWOT Analysis
  • 11.2 Astellas Pharma Inc
    • 11.2.1 Company Overview
    • 11.2.2 Product Overview
    • 11.2.3 Financial Overview
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
  • 11.3 Allergan PLC
    • 11.3.1 Company Overview
    • 11.3.2 Product Overview
    • 11.3.3 Financial Overview
    • 11.3.4 Key Development
    • 11.3.5 SWOT Analysis
  • 11.4 Pfizer
    • 11.4.1 Company Overview
    • 11.4.2 Product/Business Segment Overview
    • 11.4.3 Financial Overview
    • 11.4.4 Key Development
    • 11.4.5 SWOT Analysis
  • 11.5 PfBausch + Lomb
    • 11.5.1 Company Overview
    • 11.5.2 Product Overview
    • 11.5.3 Financial overview
    • 11.5.4 Key Developments
  • 11.6 Gilead Sciences Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Product Overview
    • 11.6.3 Financial Overview
    • 11.6.4 Key Developments
  • 11.7 Gilead Sciences Inc.
    • 11.7.1 Overview
    • 11.7.2 Product Overview
    • 11.7.3 Financial
    • 11.7.4 Key Developments
    • 11.7.5 SWOT Analysis
  • 11.8 Others

Chapter 12 MRFR Conclusion

  • 12.1 Key Findings
    • 12.1.1 From CEO's View Point
    • 12.1.2 Unmet Needs of the Market
  • 12.2 Key Companies to Watch
  • 12.3 Prediction of Medical End Users Industry

Chapter 13 Appendix

List of Tables

  • TABLE 1 Juvenile Macular Degeneration (Stargardt Disease) Industry Synopsis, 2017 - 2023
  • TABLE 2 Global Juvenile Macular Degeneration (Stargardt Disease) Market Estimates and Forecast, 2017 - 2023, (USD Million)
  • TABLE 3 Global Juvenile Macular Degeneration (Stargardt Disease) Market by Region, 2017 - 2023, (USD Million)
  • TABLE 4 Global Juvenile Macular Degeneration (Stargardt Disease) Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 5 Global Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 6 Global Juvenile Macular Degeneration (Stargardt Disease) Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 7 North America Juvenile Macular Degeneration (Stargardt Disease) Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 8 North America Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 9 North America Juvenile Macular Degeneration (Stargardt Disease) Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 10 US Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 11 US Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 12 US Juvenile Macular Degeneration (Stargardt Disease) Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 13 Canada Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 14 Canada Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 15 Canada Juvenile Macular Degeneration (Stargardt Disease) Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 16 South America Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 17 South America Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 18 South America Juvenile Macular Degeneration (Stargardt Disease) Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 19 Europe Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 20 Europe Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 21 Europe Juvenile Macular Degeneration (Stargardt Disease) Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 22 Western Europe Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 23 Western Europe Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 24 Western Europe Juvenile Macular Degeneration (Stargardt Disease) Market by End Userss, 2017 - 2023, (USD Million)
  • TABLE 25 Eastern Europe Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 26 Eastern Europe Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 27 Eastern Europe Juvenile Macular Degeneration (Stargardt Disease) Market by End Userss, 2017 - 2023, (USD Million)
  • TABLE 28 Asia Pacific Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 29 Asia Pacific Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 30 Asia Pacific Juvenile Macular Degeneration (Stargardt Disease) Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 31 Middle East & Africa Market by Diagnosis, 2017 - 2023, (USD Million)
  • TABLE 32 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Market by Devices, 2017 - 2023, (USD Million)
  • TABLE 33 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Market by End Userss, 2017 - 2023, (USD Million)

List of Figures

  • FIGURE 1 Research Process
  • FIGURE 2 Segmentation for Global Juvenile Macular Degeneration (Stargardt Disease) Market
  • FIGURE 3 Segmentation Market Dynamics for Global Juvenile Macular Degeneration (Stargardt Disease) Market
  • FIGURE 4 Global Juvenile Macular Degeneration (Stargardt Disease) market Share, by Type 2016
  • FIGURE 5 Global Juvenile Macular Degeneration (Stargardt Disease) market Share, by Devices 2016
  • FIGURE 6 Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by End Userss, 2016
  • FIGURE 7 Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Region, 2016
  • FIGURE 8 North America Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Country, 2016
  • FIGURE 9 Europe Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Country, 2016
  • FIGURE 10 Asia Pacific Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Country, 2016
  • FIGURE 11 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Country, 2016
  • FIGURE 12 Global Juvenile Macular Degeneration (Stargardt Disease) Market: Company Share Analysis, 2016 (%)
  • FIGURE 13 Merck: Key Financials
  • FIGURE 14 Merck: Segmental Revenue
  • FIGURE 15 Merck: Geographical Revenue
  • FIGURE 16 Astellas Pharma Inc. Key Financials
  • FIGURE 17 Astellas Pharma Inc. Segmental Revenue
  • FIGURE 18 Astellas Pharma Inc. Geographical Revenue
  • FIGURE 19 Bayer: Key Financials
  • FIGURE 20 Bayer: Segmental Revenue
  • FIGURE 21 Bayer: Geographical Revenue
  • FIGURE 22 Pfizer: Key Financials
  • FIGURE 23 Pfizer: Segmental Revenue
  • FIGURE 24 Pfizer: Geographical Revenue
  • FIGURE 25 Bausch + Lomb: Key Financials
  • FIGURE 26 Bausch + Lomb: Segmental Revenue
  • FIGURE 27 Bausch + Lomb: Geographical Revenue
  • FIGURE 28 Gilead Sciences Inc.: Key Financials
  • FIGURE 29 Gilead Sciences Inc.: Segmental Revenue
  • FIGURE 30 Gilead Sciences Inc.: Geographical Revenue
  • FIGURE 31 Gilead Sciences Inc.: Key Financials
Back to Top